Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label, Randomized, Dose Finding and Dose Expansion Study of Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06190899 is registered in ClinicalTrials.gov with Celcuity Inc as lead sponsor.

NCT NCT06190899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06190899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label, Randomized, Dose Finding and Dose Expansion Study of Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Lead sponsor
Celcuity Inc
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 1, 2024
Completion date
January 31, 2030
Enrollment
54 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

genital diseases, male, mcrpc (metastatic castration-resistant prostate cancer), prostate cancer, prostatic disease, prostatic neoplasms, castration-resistant, urogenital diseases, male